Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338803 · ClinicalTrials.gov registry record
Real World Glycemic Effectiveness of Linagliptin
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 11,001
- Enrollment target
NCT03338803: Completed study, sponsored by Boehringer Ingelheim.
NCT03338803 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 11,001 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03338803 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 11,001 participants
- Enrollment target
Study Summary
A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectiveness
Primary Outcome
Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years). Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date.
Interventions
- DRUG Linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,001 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2018-02-02 |
What the finished NCT03338803 record still lists
NCT03338803 is an observational study that tracks outcomes without assigning an intervention. Its 11,001 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Linagliptin is the first listed.
NCT03338803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03338803 about?
NCT03338803 is a clinical study titled "Real World Glycemic Effectiveness of Linagliptin". A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectiveness
What is the current status of trial NCT03338803?
This trial is currently completed. The enrollment target is 11,001 participants. The study started on 2017-11-21. Estimated completion is 2018-02-02.
What interventions are being tested in trial NCT03338803?
The interventions under investigation include: Linagliptin (DRUG).
Who is sponsoring clinical trial NCT03338803?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI